Bone remodeling: Multiple cellular interactions required for coupling of bone formation and resorption

Seminars in Cell and Developmental Biology

Volumn 19, Issue 5, 2008, Pages 444-451

  Sims, Natalie A ^a   Gooi, Jonathan H ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Bone remodeling; Coupling; Osteoblast; Osteoclast; Osteocyte

Indexed keywords

EPHRIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPONTIN; PARATHYROID HORMONE RELATED PROTEIN; PROSTAGLANDIN E2; SCLEROSTIN;

BONE MINERALIZATION; BONE REMODELING; CELL INTERACTION; CHEMOTAXIS; HUMAN; NONHUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOCYTE; OSTEOLYSIS; PHAGOCYTE; PROTEIN EXPRESSION; REVIEW;

EID: 53849106456     PISSN: 10849521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.semcdb.2008.07.016     Document Type: Review

References (109)

1. Walkley C.R., Shea J.M., Sims N.A., Purton L.E., and Orkin S.H. Rb regulates interactions between hematopoietic stem cells and their bone marrow microenvironment. Cell 129 (2007) 1081-1095
2. Lips P., Courpron P., and Meunier P.J. Mean wall thickness of trabecular bone packets in the human iliac crest: changes with age. Calcif Tissue Res 26 (1978) 13-17
3. Corral D.A., Amling M., Priemel M., Loyer E., Fuchs S., Ducy P., et al. Dissociation between bone resorption and bone formation in osteopenic transgenic mice. Proc Natl Acad Sci USA 95 (1998) 13835-13840
4. Kong Y.Y., Feige U., Sarosi I., Bolon B., Tafuri A., Morony S., et al. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402 (1999) 304-309
5. Dougall W.C., Glaccum M., Charrier K., Rohrbach K., Brasel K., De Smedt T., et al. RANK is essential for osteoclast and lymph node development. Genes Dev 13 (1999) 2412-2424
6. Gillespie M.T. Impact of cytokines and T lymphocytes upon osteoclast differentiation and function. Arthritis Res Ther 9 (2007) 103
7. Horowitz M.C., and Lorenzo J.A. B lymphocytes and the skeleton. Ann NY Acad Sci 1117 (2007) 82-93
8. Elefteriou F. Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 473 (2008) 231-236
9. Suda T., Takahashi N., Udagawa N., Jimi E., Gillespie M.T., and Martin T.J. Modulation of osteoclast differentiation and function by the new members of the tumor necrosis factor receptor and ligand families. Endocr Rev 20 (1999) 345-357
10. Bucay N., Sarosi I., Dunstan C.R., Morony S., Tarpley J., Capparelli C., et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification. Genes Dev 12 (1998) 1260-1268
11. Pivonka P., Zimak J., Smith D.W., Gardiner B.S., Dunstan C.R., Sims N.A., et al. Model structure and control of bone remodeling: a theoretical study. Bone 43 (2008) 249-263
12. Yasuda H., Shima N., Nakagawa N., Mochizuki S.I., Yano K., Fujise N., et al. Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG/OCIF inhibits osteoclastogenesis in vitro. Endocrinology 139 (1998) 1329-1337
13. Horwood N.J., Elliott J., Martin T.J., and Gillespie M.T. Osteotropic agents regulate the expression of osteoclast differentiation factor and osteoprotegerin in osteoblastic stromal cells. Endocrinology 139 (1998) 4743-4746
14. Palmqvist P., Persson E., Conaway H.H., and Lerner U.H. IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-kappa B ligand, osteoprotegerin, and receptor activator of NF-kappa B in mouse calvariae. J Immunol 169 (2002) 3353-3362
15. Liu B.Y., Guo J., Lanske B., Divieti P., Kronenberg H.M., and Bringhurst F.R. Conditionally immortalized murine bone marrow stromal cells mediate parathyroid hormone-dependent osteoclastogenesis in vitro. Endocrinology 139 (1998) 1952-1964
16. Lee S.H., Rho J., Jeong D., Sul J.Y., Kim T., Kim N., et al. v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation. Nat Med 12 (2006) 1403-1409
17. Mocsai A., Humphrey M.B., Van Ziffle J.A., Hu Y., Burghardt A., Spusta S.C., et al. The immunomodulatory adapter proteins DAP12 and Fc receptor gamma-chain (FcRgamma) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc Natl Acad Sci USA 101 (2004) 6158-6163
18. Kukita T., Wada N., Kukita A., Kakimoto T., Sandra F., Toh K., et al. RANKL-induced DC-STAMP is essential for osteoclastogenesis. J Exp Med 200 (2004) 941-946
19. Simonet W.S., Lacey D.L., Dunstan C.R., Kelley M., Chang M.S., Luthy R., et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89 (1997) 309-319
20. Tsuda E., Goto M., Mochizuki S., Yano K., Kobayashi F., Morinaga T., et al. Isolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis. Biochem Biophys Res Commun 234 (1997) 137-142
21. Van Wesenbeeck L., Odgren P.R., MacKay C.A., D'Angelo M., Safadi F.F., Popoff S.N., et al. The osteopetrotic mutation toothless (tl) is a loss-of-function frameshift mutation in the rat Csf1 gene: evidence of a crucial role for CSF-1 in osteoclastogenesis and endochondral ossification. Proc Natl Acad Sci USA 99 (2002) 14303-14308
22. Wiktor-Jedrzejczak W., Bartocci A., Ferrante Jr. A.W., Ahmed-Ansari A., Sell K.W., Pollard J.W., et al. Total absence of colony-stimulating factor 1 in the macrophage-deficient osteopetrotic (op/op) mouse. Proc Natl Acad Sci USA 87 (1990) 4828-4832
23. Arai F., Miyamoto T., Ohneda O., Inada T., Sudo T., Brasel K., et al. Commitment and differentiation of osteoclast precursor cells by the sequential expression of c-Fms and receptor activator of nuclear factor kappaB (RANK) receptors. J Exp Med 190 (1999) 1741-1754
24. Parfitt A.M. Targeted and nontargeted bone remodeling: relationship to basic multicellular unit origination and progression. Bone 30 (2002) 5-7
25. Mori S., and Burr D.B. Increased intracortical remodeling following fatigue damage. Bone 14 (1993) 103-109
26. Martin R.B. Targeted bone remodeling involves BMU steering as well as activation. Bone 40 (2007) 1574-1580
27. Verborgt O., Tatton N.A., Majeska R.J., and Schaffler M.B. Spatial distribution of Bax and Bcl-2 in osteocytes after bone fatigue: complementary roles in bone remodeling regulation?. J Bone Miner Res 17 (2002) 907-914
28. Noble B.S., Peet N., Stevens H.Y., Brabbs A., Mosley J.R., Reilly G.C., et al. Mechanical loading: biphasic osteocyte survival and targeting of osteoclasts for bone destruction in rat cortical bone. Am J Physiol Cell Physiol 284 (2003) C934-C943
29. Mann V., Huber C., Kogianni G., Jones D., and Noble B. The influence of mechanical stimulation on osteocyte apoptosis and bone viability in human trabecular bone. J Musculoskelet Neuronal Interact 6 (2006) 408-417
30. Tatsumi S., Ishii K., Amizuka N., Li M., Kobayashi T., Kohno K., et al. Targeted ablation of osteocytes induces osteoporosis with defective mechanotransduction. Cell Metab 5 (2007) 464-475
31. Kamioka H., Honjo T., and Takano-Yamamoto T. A three-dimensional distribution of osteocyte processes revealed by the combination of confocal laser scanning microscopy and differential interference contrast microscopy. Bone 28 (2001) 145-149
32. You L., Temiyasathit S., Lee P., Kim C.H., Tummala P., Yao W., et al. Osteocytes as mechanosensors in the inhibition of bone resorption due to mechanical loading. Bone 42 (2008) 172-179
33. Kurata K., Heino T.J., Higaki H., and Vaananen H.K. Bone marrow cell differentiation induced by mechanically damaged osteocytes in 3D gel-embedded culture. J Bone Miner Res 21 (2006) 616-625
34. Kogianni G., Mann V., and Noble B.S. Apoptotic bodies convey activity capable of initiating osteoclastogenesis and localised bone destruction. J Bone Miner Res (2008)
35. Kobayashi K., Takahashi N., Jimi E., Udagawa N., Takami M., Kotake S., et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191 (2000) 275-286
36. Malone J.D., Teitelbaum S.L., Griffin G.L., Senior R.M., and Kahn A.J. Recruitment of osteoclast precursors by purified bone matrix constituents. J Cell Biol 92 (1982) 227-230
37. Ducy P., Desbois C., Boyce B., Pinero G., Story B., Dunstan C., et al. Increased bone formation in osteocalcin-deficient mice. Nature 382 (1996) 448-452
38. Massy Z.A., Mentaverri R., Mozar A., Brazier M., and Kamel S. The pathophysiology of vascular calcification: are osteoclast-like cells the missing link?. Diabetes Metab 34 Suppl. 1 (2008) S16-S20
39. Henriksen K., Leeming D.J., Byrjalsen I., Nielsen R.H., Sorensen M.G., Dziegiel M.H., et al. Osteoclasts prefer aged bone. Osteoporos Int 18 (2007) 751-759
40. Yu X., Huang Y., Collin-Osdoby P., and Osdoby P. Stromal cell-derived factor-1 (SDF-1) recruits osteoclast precursors by inducing chemotaxis, matrix metalloproteinase-9 (MMP-9) activity, and collagen transmigration. J Bone Miner Res 18 (2003) 1404-1418
41. Yu X., Huang Y., Collin-Osdoby P., and Osdoby P. CCR1 chemokines promote the chemotactic recruitment, RANKL development, and motility of osteoclasts and are induced by inflammatory cytokines in osteoblasts. J Bone Miner Res 19 (2004) 2065-2077
42. Guise T.A., Mohammad K.S., Clines G., Stebbins E.G., Wong D.H., Higgins L.S., et al. Basic mechanisms responsible for osteolytic and osteoblastic bone metastases. Clin Cancer Res 12 (2006) 6213s-6216s
43. Aggarwal R., Ghobrial I.M., and Roodman G.D. Chemokines in multiple myeloma. Exp Hematol 34 (2006) 1289-1295
44. Chambers T.J., Darby J.A., and Fuller K. Mammalian collagenase predisposes bone surfaces to osteoclastic resorption. Cell Tissue Res 241 (1985) 671-675
45. Chambers T.J., and Fuller K. Bone cells predispose bone surfaces to resorption by exposure of mineral to osteoclastic contact. J Cell Sci 76 (1985) 155-165
46. Hauge E.M., Qvesel D., Eriksen E.F., Mosekilde L., and Melsen F. Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers. J Bone Miner Res 16 (2001) 1575-1582
47. Parfitt A.M. Misconceptions V-activation of osteoclasts is the first step in the bone remodelling cycle. Bone 39 (2006) 1170-1172
48. Eriksen E.F., Eghbali-Fatourechi G.Z., and Khosla S. Remodeling and vascular spaces in bone. J Bone Miner Res 22 (2007) 1-6
49. Sacchetti B., Funari A., Michienzi S., Di Cesare S., Piersanti S., Saggio I., et al. Self-renewing osteoprogenitors in bone marrow sinusoids can organize a hematopoietic microenvironment. Cell 131 (2007) 324-336
50. Parfitt A.M. The bone remodeling compartment: a circulatory function for bone lining cells. J Bone Miner Res 16 (2001) 1583-1585
51. Sathyanarayana P., Menon M.P., Bogacheva O., Bogachev O., Niss K., Kapelle W.S., et al. Erythropoietin modulation of podocalyxin and a proposed erythroblast niche. Blood 110 (2007) 509-518
52. Sims N.A., Walker E.C., Poulton I.J., Mcgregor N.E., Gillespie M.T., and Martin T.J. Oncostatin M is an essential stimulus of bone formation and osteoclastogenesis. J Bone Miner Res 22 (2007) S19
53. Ross F.P., and Teitelbaum S.L. Alphavbeta3 and macrophage colony-stimulating factor: partners in osteoclast biology. Immunol Rev 208 (2005) 88-105
54. Horne W.C., Sanjay A., Bruzzaniti A., and Baron R. The role(s) of Src kinase and Cbl proteins in the regulation of osteoclast differentiation and function. Immunol Rev 208 (2005) 106-125
55. Gil-Henn H., Destaing O., Sims N.A., Aoki K., Alles N., Neff L., et al. Defective microtubule-dependent podosome organization in osteoclasts leads to increased bone density in Pyk2(-/-) mice. J Cell Biol 178 (2007) 1053-1064
56. Malaval L., Wade-Gueye N.M., Boudiffa M., Fei J., Zirngibl R., Chen F., et al. Bone sialoprotein plays a functional role in bone formation and osteoclastogenesis. J Exp Med (2008)
57. Ihara H., Denhardt D.T., Furuya K., Yamashita T., Muguruma Y., Tsuji K., et al. Parathyroid hormone-induced bone resorption does not occur in the absence of osteopontin. J Biol Chem 276 (2001) 13065-13071
58. Chellaiah M.A., Kizer N., Biswas R., Alvarez U., Strauss-Schoenberger J., Rifas L., et al. Osteopontin deficiency produces osteoclast dysfunction due to reduced CD44 surface expression. Mol Biol Cell 14 (2003) 173-189
59. Weilbaecher K.N., Motyckova G., Huber W.E., Takemoto C.M., Hemesath T.J., Xu Y., et al. Linkage of M-CSF signaling to Mitf, TFE3, and the osteoclast defect in Mitf(mi/mi) mice. Mol Cell 8 (2001) 749-758
60. Meadows N.A., Sharma S.M., Faulkner G.J., Ostrowski M.C., Hume D.A., and Cassady A.I. The expression of Clcn7 and Ostm1 in osteoclasts is coregulated by microphthalmia transcription factor. J Biol Chem 282 (2007) 1891-1904
61. Wong B.R., Besser D., Kim N., Arron J.R., Vologodskaia M., Hanafusa H., et al. TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. Mol Cell 4 (1999) 1041-1049
62. Chamoux E., Houde N., L'Eriger K., and Roux S. Osteoprotegerin decreases human osteoclast apoptosis by inhibiting the TRAIL pathway. J Cell Physiol (2008)
63. Tran Van P., Vignery A., and Baron R. An electron-microscopic study of the bone-remodeling sequence in the rat. Cell Tissue Res 225 (1982) 283-292
64. Everts V., Delaisse J.M., Korper W., Jansen D.C., Tigchelaar-Gutter W., Saftig P., et al. The bone lining cell: its role in cleaning Howship's lacunae and initiating bone formation. J Bone Miner Res 17 (2002) 77-90
65. Gray C., Boyde A., and Jones S.J. Topographically induced bone formation in vitro: implications for bone implants and bone grafts. Bone 18 (1996) 115-123
66. Dalby M.J., McCloy D., Robertson M., Wilkinson C.D., and Oreffo R.O. Osteoprogenitor response to defined topographies with nanoscale depths. Biomaterials 27 (2006) 1306-1315
67. Mohan S., and Baylink D.J. Bone growth factors. Clin Orthop Relat Res (1991) 30-48
68. Hauschka P.V., Mavrakos A.E., Iafrati M.D., Doleman S.E., and Klagsbrun M. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-sepharose. J Biol Chem 261 (1986) 12665-12674
69. Schmid C., Schlapfer I., Futo E., Waldvogel M., Schwander J., Zapf J., et al. Triiodothyronine (T3) stimulates insulin-like growth factor (IGF)-1 and IGF binding protein (IGFBP)-2 production by rat osteoblasts in vitro. Acta Endocrinol (Copenh) 126 (1992) 467-473
70. Rodan G.A. Introduction to bone biology. Bone 13 Suppl. 1 (1992) S3-S6
71. Centrella M., McCarthy T.L., and Canalis E. Transforming growth factor-beta and remodeling of bone. J Bone Joint Surg Am 73 (1991) 1418-1428
72. Harris S.E., Harris M.A., Mahy P., Wozney J., Feng J.Q., and Mundy G.R. Expression of bone morphogenetic protein messenger RNAs by normal rat and human prostate and prostate cancer cells. Prostate 24 (1994) 204-211
73. Vukicevic S., Latin V., Chen P., Batorsky R., Reddi A.H., and Sampath T.K. Localization of osteogenic protein-1 (bone morphogenetic protein-7) during human embryonic development: high affinity binding to basement membranes. Biochem Biophys Res Commun 198 (1994) 693-700
74. Vukicevic S., Paralkar V.M., Cunningham N.S., Gutkind J.S., and Reddi A.H. Autoradiographic localization of osteogenin binding sites in cartilage and bone during rat embryonic development. Dev Biol 140 (1990) 209-214
75. Rydziel S., Ladd C., McCarthy T.L., Centrella M., and Canalis E. Determination and expression of platelet-derived growth factor-AA in bone cell cultures. Endocrinology 130 (1992) 1916-1922
76. Demiralp B., Chen H.L., Koh A.J., Keller E.T., and McCauley L.K. Anabolic actions of parathyroid hormone during bone growth are dependent on c-fos. Endocrinology 143 (2002) 4038-4047
77. Dai X.M., Zong X.H., Akhter M.P., and Stanley E.R. Osteoclast deficiency results in disorganized matrix, reduced mineralization, and abnormal osteoblast behavior in developing bone. J Bone Miner Res 19 (2004) 1441-1451
78. Koga T., Inui M., Inoue K., Kim S., Suematsu A., Kobayashi E., et al. Costimulatory signals mediated by the ITAM motif cooperate with RANKL for bone homeostasis. Nature 428 (2004) 758-763
79. Sims N.A., Jenkins B.J., Nakamura A., Quinn J.M., Li R., Gillespie M.T., et al. Interleukin-11 receptor signaling is required for normal bone remodeling. J Bone Miner Res 20 (2005) 1093-1102
80. Bollerslev J., Steiniche T., Melsen F., and Mosekilde L. Structural and histomorphometric studies of iliac crest trabecular and cortical bone in autosomal dominant osteopetrosis: a study of two radiological types. Bone 10 (1989) 19-24
81. Del Fattore A., Peruzzi B., Rucci N., Recchia I., Cappariello A., Longo M., et al. Clinical, genetic, and cellular analysis of 49 osteopetrotic patients: implications for diagnosis and treatment. J Med Genet 43 (2006) 315-325
82. Marzia M., Sims N.A., Voit S., Migliaccio S., Taranta A., Bernardini S., et al. Decreased c-Src expression enhances osteoblast differentiation and bone formation. J Cell Biol 151 (2000) 311-320
83. Martin T.J., and Sims N.A. Osteoclast-derived activity in the coupling of bone formation to resorption. Trends Mol Med 11 (2005) 76-81
84. Zhao C., Irie N., Takada Y., Shimoda K., Miyamoto T., Nishiwaki T., et al. Bidirectional ephrinB2-EphB4 signaling controls bone homeostasis. Cell Metab 4 (2006) 111-121
85. Karsdal M.A., Neutzsky-Wulff A.V., Dziegiel M.H., Christiansen C., and Henriksen K. Osteoclasts secrete non-bone derived signals that induce bone formation. Biochem Biophys Res Commun 366 (2008) 483-488
86. Walker EC, McGregror NE, Poulton IJ, Pompolo S, Allan EH, Quinn JMW, et al. Cardiotrophin-1 is an osteoclast-derived stimulus of bone formation required for normal bone remodeling. J Bone Miner Res, doi:10.1359/JBMR.080706, in press.
87. Gorski J.P. Is all bone the same? Distinctive distributions and properties of non-collagenous matrix proteins in lamellar vs. woven bone imply the existence of different underlying osteogenic mechanisms. Crit Rev Oral Biol Med 9 (1998) 201-223
88. Civitelli R. Cell-cell communication in the osteoblast/osteocyte lineage. Arch Biochem Biophys 473 (2008) 188-192
89. Allan E.H., Hausler K.D., Wei T., Gooi J.H., Quinn J.M., Crimeen-Irwin B., et al. EphrinB2 regulation by parathyroid hormone (PTH) and PTHrP revealed by molecular profiling in differentiating osteoblasts. J Bone Miner Res 23 (2008) 1170-1181
90. Zhou H., Kartsogiannis V., Hu Y.S., Elliott J., Quinn J.M., McKinstry W.J., et al. A novel osteoblast-derived C-type lectin that inhibits osteoclast formation. J Biol Chem 276 (2001) 14916-14923
91. Nakamura A., Ly C., Cipetic M., Sims N.A., Vieusseux J., Kartsogiannis V., et al. Osteoclast inhibitory lectin (OCIL) inhibits osteoblast differentiation and function in vitro. Bone 40 (2007) 305-315
92. Kartsogiannis V, Sims NA, Quinn JMW, Ly C, Cipetic M, Poulton IJ, et al. Osteoclast inhibitory lectin (OCIL), an immune cell product that is required for normal bone physiology in vivo. J Biol Chem; in press.
93. Moseley J.M., Hayman J.A., Danks J.A., Alcorn D., Grill V., Southby J., et al. Immunohistochemical detection of parathyroid hormone-related protein in human fetal epithelia. J Clin Endocrinol Metab 73 (1991) 478-484
94. Suda N., Gillespie M.T., Traianedes K., Zhou H., Ho P.W., Hards D.K., et al. Expression of parathyroid hormone-related protein in cells of osteoblast lineage. J Cell Physiol 166 (1996) 94-104
95. Dobnig H., and Turner R.T. Evidence that intermittent treatment with parathyroid hormone increases bone formation in adult rats by activation of bone lining cells. Endocrinology 136 (1995) 3632-3638
96. Jilka R.L., Weinstein R.S., Bellido T., Roberson P., Parfitt A.M., and Manolagas S.C. Increased bone formation by prevention of osteoblast apoptosis with parathyroid hormone. J Clin Invest 104 (1999) 439-446
97. Amizuka N., Karaplis A.C., Henderson J.E., Warshawsky H., Lipman M.L., Matsuki Y., et al. Haploinsufficiency of parathyroid hormone-related peptide (PTHrP) results in abnormal postnatal bone development. Dev Biol 175 (1996) 166-176
98. Miao D., He B., Jiang Y., Kobayashi T., Soroceanu M.A., Zhao J., et al. Osteoblast-derived PTHrP is a potent endogenous bone anabolic agent that modifies the therapeutic efficacy of administered PTH 1-34. J Clin Invest 115 (2005) 2402-2411
99. Balemans W., Ebeling M., Patel N., Van Hul E., Olson P., Dioszegi M., et al. Increased bone density in sclerosteosis is due to the deficiency of a novel secreted protein (SOST). Hum Mol Genet 10 (2001) 537-543
100. Balemans W., Patel N., Ebeling M., Van Hul E., Wuyts W., Lacza C., et al. Identification of a 52 kb deletion downstream of the SOST gene in patients with van Buchem disease. J Med Genet 39 (2002) 91-97
101. Loots G.G., Kneissel M., Keller H., Baptist M., Chang J., Collette N.M., et al. Genomic deletion of a long-range bone enhancer misregulates sclerostin in Van Buchem disease. Genome Res 15 (2005) 928-935
102. van Bezooijen R.L., Roelen B.A., Visser A., van der Wee-Pals L., de Wilt E., Karperien M., et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199 (2004) 805-814
103. Winkler D.G., Sutherland M.K., Geoghegan J.C., Yu C., Hayes T., Skonier J.E., et al. Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22 (2003) 6267-6276
104. Sutherland M.K., Geoghegan J.C., Yu C., Turcott E., Skonier J.E., Winkler D.G., et al. Sclerostin promotes the apoptosis of human osteoblastic cells: a novel regulation of bone formation. Bone 35 (2004) 828-835
105. Robling A.G., Bellido T., and Turner C.H. Mechanical stimulation in vivo reduces osteocyte expression of sclerostin. J Musculoskelet Neuronal Interact 6 (2006) 354
106. Keller H., and Kneissel M. SOST is a target gene for PTH in bone. Bone 37 (2005) 148-158
107. Bellido T., Ali A.A., Gubrij I., Plotkin L.I., Fu Q., O'Brien C.A., et al. Chronic elevation of parathyroid hormone in mice reduces expression of sclerostin by osteocytes: a novel mechanism for hormonal control of osteoblastogenesis. Endocrinology 146 (2005) 4577-4583
108. Feng J.Q., Ward L.M., Liu S., Lu Y., Xie Y., Yuan B., et al. Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38 (2006) 1310-1315
109. Yuan B., Takaiwa M., Clemens T.L., Feng J.Q., Kumar R., Rowe P.S., et al. Aberrant Phex function in osteoblasts and osteocytes alone underlies murine X-linked hypophosphatemia. J Clin Invest 118 (2008) 722-734